50th ASH Annual Meeting and Exposition (December 6 - 9, 2008): Clinical Care - Recurrence, Secondary Neoplasia, and Late Complications after Transplantation

Monday, December 8, 2008: 11:00 AM-12:30 PM

304-306-308 - South (Moscone Center)

Moderators:

Navneet S. Majhail, MD, MS and David Jacobsohn, MD

11:00 AM

Genetic Allelic Variation in the p53 DNA Repair Pathway Constitute a Risk Factor for Long-Term Survival in Hematopoietic Stem Cell Transplantation

Stig E. Bojesen¹^*, Mari Malkki²^*, Ted Gooley³^*, Lue Ping Zhao³^*, Annamalai Selvakumar⁴^*, Stephen R Spellman, MS⁵^*, Effie W Petersdorf, MD²^*, John A. Hansen, MD⁶ and Bo Dupont⁷^*

¹Clinical Biochemistry, Copenhagen University Hospital, Herlev, Herlev, Denmark
²Fred Hutchinson Cancer Research Center, Seattle, WA
³Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA
⁴Immunology Program, Memorial Sloan-Kettering Cancer Center, New York, NY
⁵National Marrow Donor Program, Minneapolis, MN
⁶Fred Hutchinson Cancer Rsch. Ctr., Seattle, WA
⁷Sloan-Kettering Institute, Memorial Sloan-Kettering Cancer Center, New York, NY

11:15 AM

338

Clinical Relevance of Minimal Residual Disease and Chimerism for the Detection of Relapse after Hematopoietic Stem Cell Transplantation

Bernd Gruhn¹^*, Juliane Sanft²^*, Nadine Pfaffendorf¹^*, Ilona Wolff¹^*, Dietlinde Fuchs¹^*, Felix Zintl¹^* and James Beck¹^*

¹Department of Pediatrics, University of Jena, Jena, Germany
²Institute for Forensic Medicine, University of Jena, Jena, Germany

11:30 AM

339

Second Allogeneic Hematopoietic Stem Cell Transplantation for Relapse of Malignant Disease: Retrospective Analysis of Outcome and Predictive Factors

Tapani Ruutu¹, Ronald Brand²^*, Anja van Biezen²^*, Vanderson Rocha³^*, Anna Sureda⁴^*, André Tichelli⁵^*, Hermann Einsele⁶^*, Giorgio Dini⁷^*, Marco Bregni⁸^*, Laurent Garderet⁹^*, Jane Apperley¹⁰^*, Alois Gratwohl⁵^*, Dietger Niederwieser¹¹^* and Theo de Witte¹²^*

¹Department of Medicine, Helsinki University Central Hospital, Helsinki, Finland
²Department of Medical Statistics & Bioinformatics, Leiden University Medical Centre, Leiden, Netherlands
³Department of Hematology - BMT, Hopital St. Louis, Paris, France
⁴Clinical Hematology Division, Hospital Santa Creu i Sant Pau, Barcelona, Spain
⁵Hematology, University Hospital, Basel, Switzerland
⁶Medizinische Klinik und Poliklinik II, Universitätsklinik Wuerzburg, Wuerzburg, Germany
⁷Institute G. Gaslini, Genova, Italy
⁸San Raffaele Scientific Institute, Milan, Italy
⁹Department of Hematology, Hopital Saint Antoine, Paris, France
¹⁰Department of Haematology, Imperial College, London, United Kingdom
¹¹Division of Haematology & Oncology, University Hospital Leipzig, Leipzig, Germany
¹²Department of Hematology, Radboud University - Nijmegen Medical Centre, Nijmegen, Netherlands

11:45 AM

340

Monitoring of Donor Chimerism in CD34+ Peripheral Blood Progenitors Allows to Detect Minimal Residual Disease after Allogeneic Stem Cell Transplantation -Results of a Randomized Trial-

Martin Bornhaeuser¹^*, Uta Oelschlaegel¹^*, Gesine Bug²^*, Uwe Platzbecker³, Karin Lutterbeck¹^*, Michael G Kiehl⁴^*, Johannes Schetelig¹^*, Alexander Kiani¹^*, Thomas Illmer⁵, Markus Schaich, MD⁶, Catrin Theuser¹^*, Brigitte Mohr¹^*, Cornelia Brendel⁷^*, Axel A Fauser⁴, Stefan Klein²^*, Hans Martin²^*, Gerhard Ehninger, MD⁸ and Christian Thiede¹^*

¹Hematology, University Hospital, Dresden, Germany
²Hematology/Oncology, University Hospital, Frankfurt, Germany
³University Hospital Dresden, Germany
⁴BMT Clinic, Idar-Oberstein, Germany
⁵Medizinische Klinik I, University Hospital Carl Gustav Carus, Dresden University of Technology, Dresden, Germany
⁶Medical Department 1, University Hospital, Dresden, Germany
⁷Hematology/Oncology, University Hospital Marburg
⁸Universitatsklinikum Carl Gustav Carus, Dresden, Germany

12:00 PM

341

Impact of Pretransplant Cytogenetics and Marrow Remission Status on Outcome of Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Allogeneic Stem Cell Transplantation Conditioned with Busulfan and Fludarabine

Ebru Koca^*, Rima M Saliba^*, Marcos De Lima, Uday Popat^*, Partow Kebriaei, Gabriela Rondon^*, Sergio Giralt, Borje S Andersson^* and Richard E Champlin^*

Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, TX

12:15 PM

342

Safety Trial of NK Cell Enhanced Donor Lymphocyte Infusions from a 3-5/6 HLA Matched Family Member Following Nonmyeloablative Allogeneic Stem Cell Transplantation

David A. Rizzieri, MD, Robert Storms, Ph.D^*, Daniel Nikcevich, MD, PhD, Bercedis Peterson, Ph.D^*, Debashish Misra, MD^*, Christine Apple^*, Megan Baker^*, Cristina Gasparetto, MD, Mitchell Horwitz, MD, John Chute, MD, Ashley Morris, PharmD.^* and Nelson J. Chao, MD

Department of Medicine, Duke University Medical Center, Durham, NC

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

723.O1.6 Clinical Care - Recurrence, Secondary Neoplasia, and Late Complications after Transplantation